FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis

BACKGROUND: Tamoxifen is an important choice in endocrine therapy for patients with oestrogen receptor-positive (ER+) breast cancer, and disease progression-associated resistance to tamoxifen therapy is still challenging. Flap endonuclease-1 (FEN1) is used as a prognostic biomarker and is considered...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: Xu, Lu, Shen, Ji-Ming, Qu, Jing-Lei, Song, Na, Che, Xiao-Fang, Hou, Ke-Zuo, Shi, Jing, Zhao, Lei, Shi, Sha, Liu, Yun-Peng, Qu, Xiu-Juan, Teng, Yue-E
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940940/
https://ncbi.nlm.nih.gov/pubmed/33708885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-3068
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados